Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOEST-3
2022-502140-13-00Phase 4Authorised
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised trial of edoxaban in Atrial fibrillation (AFib), acute coronary syndrome (ACS) and Chronic Coronary Syndrome (CCS) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Primary safety endpoint and Co-primary efficacy endpoint. Planned start Nov 2022; status: authorised.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on 2022-502140-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502140-13-00.